Stocks-CRSP-CRISPR Therapeutics AG

CRSP CRISPR Therapeutics AG

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: CRISPR Therapeutics AG's revenues decreased by 99.87% and amounted to 1.20M. Net income decreased by 272.16% to -650.18M. Net assets decreased by NaN to N/A and EPS decreased from 4.70 to -8.36.
CRSP's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
32.69%
Net Profit Margin
-25,682.05%
Operating Margin
-235.43%
Return On Investment
-7.50%